Semaphorin

Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors

Retrieved on: 
Thursday, October 26, 2023
Rosenbergia xenium, Neoplasm, Radiation therapy, Genomics, Pathology, Duke University, Health, Assistant, Custom, DMG, Glioma, BioRxiv, Professor, Brain, Radiation, Panel, Semaphorin, Patient, DMG Mori Seiki Co., DNA, Pharmaceutical industry, Medical imaging, ATM, Neurosurgery

PLEASANTON, Calif., Oct. 26, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the 10x Xenium Analyzer was used in a study recently published on bioRxiv characterizing radiation-resistance mechanisms of diffuse midline gliomas (DMGs). Led by researchers at Duke University, the study also provides a lens by which to understand clinical response in patients for current and future clinical trials using a novel kinase inhibitor as part of DMG therapeutic strategies.

Key Points: 
  • Researchers conducting the study analyzed formalin-fixed paraffin-embedded tissue sections of a mouse brain tumor model that mimics the common human DMG genetic drivers and to examine the molecular and cellular mechanisms driving radiation efficacy or resistance in these tumors.
  • The study put particular focus on the role that loss of Atm, which encodes a protein responsible for cellular response to double-stranded DNA damage, plays in treatment response.
  • Dr. Zach Reitman, lead author and Assistant Professor of Radiation Oncology, Pathology and Neurosurgery, said, "These are diffuse tumors that infiltrate the normal brain.
  • It is awesome to see our customers using Xenium in their own labs with such an incredible and immediate impact.

Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer

Retrieved on: 
Tuesday, September 26, 2023
HD, Clinical trial, Neoplasm, SEMA4D, Head, Tumor microenvironment, Brain, Semaphorin, Correlation, Dementia, PFS, Patient, CPS, PD-L1, ORR, Conference, Pharmaceutical industry

ROCHESTER, N.Y., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company will report on novel findings for its lead product, pepinemab, with implications for treatment of Alzheimer’s and other slowly progressive neurodegenerative diseases and for cancer immunotherapy at two upcoming Medical Conferences.

Key Points: 
  • ROCHESTER, N.Y., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company will report on novel findings for its lead product, pepinemab, with implications for treatment of Alzheimer’s and other slowly progressive neurodegenerative diseases and for cancer immunotherapy at two upcoming Medical Conferences.
  • Vaccinex completed enrollment in the randomized, double-blind SIGNAL-AD phase 1/2a study ( NCT04381468 ) for early AD in May 2023.
  • A second such drug from Eli Lilly, donanemab, has reported equivalent data and may be FDA approved before year end.
  • We believe that a similar effect is likely for addition of chemotherapy to treatment with pepinemab in combination with KEYTRUDA.

aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies

Retrieved on: 
Thursday, September 29, 2022
Therapy, Inflammation, RNA transfection, LIFE, COVID-19, Risk, IND, Antibody, Chemokine, Semaphorin, Private Securities Litigation Reform Act, VEGF, Forward-looking statement, Program, ATyr Pharma, Cancer, USPTO, Biology, Goal, Patent, Method, SAN, Research, GLOBE, SEC, NRP2, Generic drug, Pharmaceutical industry

16/376,979 titled, Compositions and methods comprising anti-NRP2 antibodies, covers the use of a series of antibodies targeting NRP2 for differentiated therapeutic applications in the areas of cancer and inflammation.

Key Points: 
  • 16/376,979 titled, Compositions and methods comprising anti-NRP2 antibodies, covers the use of a series of antibodies targeting NRP2 for differentiated therapeutic applications in the areas of cancer and inflammation.
  • The blocking antibodies that aTyr has developed target distinct domains of NRP2, including those interacting with semaphorins, VEGF and certain chemokines.
  • A Notice of Allowance is issued after the USPTO makes the determination that a patent should be granted from an application.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

Retrieved on: 
Thursday, June 10, 2021
Integral membrane proteins, Membrane proteins, Transmembrane proteins, Single-pass transmembrane proteins, Transmembrane receptors, Neuropilin 2, Neuropilin, Semaphorin, E-selectin, aTyr Pharma

The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.

Key Points: 
  • The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.
  • Class 3 Semaphorins are an important set of NRP2 ligands, with recent data implicating their role in sustaining chronic inflammation.
  • Details of the abstract and poster presentation are as follows:
    The poster is also available on the aTyr website.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Thursday, March 11, 2021
Medical specialties, Medicine, Clinical medicine, SEMA4D, Cancer treatments, Single-pass transmembrane proteins, Semaphorin, Monoclonal antibody

ROCHESTER, N.Y., March 11, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Dr. Maurice Zauderer, chief executive officer, will deliver a company presentation at the Oppenheimer 31st Annual Healthcare Conference, which is being held March 16-18, 2021.

Key Points: 
  • ROCHESTER, N.Y., March 11, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Dr. Maurice Zauderer, chief executive officer, will deliver a company presentation at the Oppenheimer 31st Annual Healthcare Conference, which is being held March 16-18, 2021.
  • A live webcast of the presentation is available at the following link during and following the conference: https://wsw.com/webcast/oppenheimer9/register.aspx?conf=oppenheimer9&pag...
    Vaccinex, Inc.is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D).
  • The Companys lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers chronic inflammation in the brain.
  • The Company additionally intends to leverage its proprietary drug discovery platform, ActivMAb, to create opportunities for future pipeline expansion and strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against difficult and important multi-pass membrane receptors including GPCR and ion channels.